Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 17/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30459062 | 1.00 | CYP1B1 (0.53) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL30455266 | 1.00 | CYP1B1 (0.53) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL29936324 | 0.88 | CYP1B1 (0.65) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL22164834 | 0.88 | CYP1B1 (0.65) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL26349189 | 0.84 | MGMT (0.42) | ALDH1A1KDM4EMEN1NPC1LMNA | |
| SCHEMBL29199650 | 0.82 | HPGD (0.49) | ALDH1A1NPC1MAPTKMT2A | |
| SCHEMBL10262375 | 0.81 | CYP1B1 (0.60) | CYP1B1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL14499669 | 0.80 | HPGD (0.50) | ALDH1A1NPC1MAPTKMT2A | |
| SCHEMBL15096384 | 0.80 | MEN1 (0.57) | ALDH1A1POLBKDM4EMEN1NPC1 | |
| SCHEMBL10267887 | 0.77 | CYP1B1 (0.68) | CYP1B1ALDH1A1POLBKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | SIGILON THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-07-11 | — | — | US | disclosed |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303502-A1 | HETEROARYL AND HETEROCYCLYL COMPOUNDS | CYP3A43, CYP2C9, CYP2C19 | CYP1B1 18/4885ALDH1A1 296/4885POLB 1454/4885 |
| US-20130178609-A1 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS | SGMS2, SGMS1, DEGS1 | CYP1B1 2972/4885ALDH1A1 4578/4885POLB 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.